Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued access ASA404 trial for patients previously treated in Novartis ASA404 studies
2009-016834-28Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vadimezan in Non-hematologic malignancy, sponsored by Novartis. Primary endpoints: Safety and Other safety assessments. Started Feb 2010; status: completed.
02
Drugs
vadimezan
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2009-016834-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016834-28.